Objectives: The aim of the present study was to evaluate the in vitro activity and synergism of the combinations of amphotericin B/caspofungin and amphotericin B/posaconazole against Candida albicans, grown either as planktonic cells or in biofilms.
Introduction
Invasive Candida infections are associated with high morbidity and mortality in immunocompromised and severely ill patients. 1 Candida may colonize surfaces of foreign inserted material, most commonly vascular catheters, but also surfaces of implants, such as artificial valves or hearts, forming persistent biofilms. Whereas percutaneous vascular catheters may be removed quickly, the removal of implanted medical devices is problematic because these implants generally have a life-supportive function. Thus, any efforts towards successful treatment and retaining the implanted device are urgently needed in clinical practice. Newly developed antifungal agents such as caspofungin and posaconazole show excellent in vitro activity against Candida planktonic cells. 2 Echinocandins, including caspofungin as the first echinocandin introduced for clinical use, were shown to be more active against Candida albicans biofilm than the azoles. 3, 4 To improve the activity against Candida biofilms and Candida biofilm-associated infections, the use of the new antifungals in combination might be more successful.
The aim of the present study was to evaluate the in vitro activity and synergism of antifungal combinations including caspofungin, posaconazole and amphotericin B against C. albicans in both growth forms, planktonic cells and biofilms. procedures and stored at 2708C. C. albicans ATCC 10231 was used as a quality control strain.
Materials and methods

Fungal isolates
Antifungal drugs
A standard antifungal powder of amphotericin B was purchased from the manufacturer (Bristol-Myers Squibb, Epernon, France), prepared in 100% DMSO at a concentration of 1000 mg/L. Caspofungin and posaconazole were purchased as the products for clinical use (Cancidas w , Merck & Co., Inc., 50 mg of powder for intravenous infusion; Noxafil w , ScheringPlough Co., 40 mg/mL oral suspension). 5 The Cancidas w powder was diluted in distilled water to 1000 mg/L. All antifungal drugs were diluted in RPMI 1640 broth with L-glutamine and without sodium bicarbonate, buffered with MOPS to final concentrations of 0.06 -16 mg/L for amphotericin B and caspofungin, and 0.06-256 mg/L for posaconazole.
In vitro activity of antifungal combinations against planktonic cells of C. albicans
The individual MICs for planktonic cells were determined using the microdilution method in accordance with the guidelines of the CLSI (formerly the NCCLS). 6 Chequerboard tests were employed to determine the efficacy of antifungal combinations. 7 The drugs used in combination were amphotericin B/caspofungin and amphotericin B/posaconazole at the concentrations described above.
MICs of individual drugs determined by visual readings correspond to either a complete (100% for amphotericin B and caspofungin) or a prominent (50% for posaconazole) decrease in turbidity compared with the growth control. MICs of drug combinations correspond to complete growth inhibition for the amphotericin B/caspofungin combination and prominent growth inhibition for the amphotericin B/posaconazole combination.
In vitro activity of antifungal combinations against biofilms of C. albicans
The effects of amphotericin B, caspofungin and posaconazole alone, and antifungal combinations of amphotericin B/caspofungin and amphotericin B/posaconazole, on C. albicans biofilms were assessed by a chequerboard microdilution method with biofilms formed in the wells of microtitre plates and an XTT-based colorimetric assay. 8 The MIC for biofilms was determined as compared with control prominent increase in optical density (OD) (by 50%) of wells containing biofilms and antifungal drugs alone or in combination.
Interpretation of drug combination interaction
Drug combination interaction was classified on the basis of the fractional inhibitory concentration index (FICI). 
Growth inhibition assay on C. albicans biofilm
To test the fungicidal activity of antifungal drugs alone or in combination against biofilms, biofilms were prepared and treated with antifungal agents as described above. After incubation with antifungal drugs, biofilms were scraped off and seeded on Sabouraud agar plates. Following incubation at 358C for 48 h, the number of cfu on each plate was determined.
Statistical analysis
Each experiment was performed in duplicate, and repeated at least three times on different days. For the growth inhibition assay the arithmetic mean and standard error obtained on three different occasions were calculated. Significance of difference (P, 0.05) was assessed using the Mann-Whitney U-test. (Table 1) . Therefore, the combination of amphotericin B/posaconazole yielded synergism against the biofilms of all 10 C. albicans isolates (FICI,0.27). The combination of amphotericin B/caspofungin yielded an indifferent interaction against all 10 C. albicans isolates (FICI 0.75 -1.25). Figure 1 shows the fungicidal activities of antifungal drugs alone and in combination. Against biofilms, amphotericin B and caspofungin at concentrations of 1 and 2 mg/L and posaconazole at concentrations of 2 and 256 mg/L failed to reduce the fungal colony counts significantly compared with the untreated control (,1 log 10 cfu/mL; P .0.05). The combination of 1 mg/L amphotericin B/2 mg/L caspofungin significantly reduced the growth of the cells in biofilm by .1 log 10 cfu/mL (P,0.05). The greatest decrease in the growth of the cells within the biofilm, reaching .2 log 10 cfu/mL (P,0.05), was achieved by the combination of 1 mg/L amphotericin B and 2 mg/L posaconazole.
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Discussion
In the present work, a chequerboard assay and fungicidal assay were used to evaluate the interaction of amphotericin B with either caspofungin or posaconazole against planktonic cells and biofilms of C. albicans in vitro. As reported in previous studies, 2 all tested antifungal agents were highly active against the planktonic cells of C. albicans. However, significant increases in the MICs of all antifungals tested were observed for C. albicans biofilms. 4, 5 The use of antifungal combinations may improve the management of Candida biofilm-associated infection, disrupt the biofilms and prevent the emergence of resistance. Bachmann et al. 9 described indifferent interaction with some trend towards additivity of the combination of amphotericin B and caspofungin against a single C. albicans isolate in vitro. However, there exist no data about the interaction of combinations of amphotericin B and the new triazole agent posaconazole against clinical Candida isolates causing invasive infections.
To our knowledge, the in vitro phenomenon of synergism of amphotericin B and posaconazole against C. albicans biofilms is reported here for the first time. Synergism against Candida biofilms was achieved due to reduction of posaconazole resistance expressed by a significant decrease in the MIC of posaconazole when used in combination with amphotericin B. There are many mechanisms for resistance of microbial cells within biofilms, although they are variable and differential. For bacteria, decreased penetration, changes in microbial metabolism and activity, and expression of resistance genes have been discussed. Some of these mechanisms may play a role in fungal biofilms, such as expression of efflux pumps involved in fluconazole resistance. 3 However, little is known about the resistance of Candida biofilms to posaconazole. Posaconazole has a unique hydrophobic structure. Biofilms are composed of a hydrophilic matrix, cells and hyphae. Hypothetically, posaconazole used together with amphotericin B may undergo some structural change affecting the biofilm matrix and the fungal cells within the biofilm. In our experiments, the effects of the antifungal combination were determined after a single incubation for 48 h only, even then leading to a significant log reduction of candidal growth.
In clinical practice, simultaneous application of two antifungals is not yet recommended for the treatment of invasive candidiasis, except for the combination of amphotericin B with flucytosine in endocarditis based on expert opinion. 10 Yet there may be circumstances where antifungal combination therapy could be of value. Persistent candidaemia originating from a biofilm-associated infection, such as endocarditis, might justify the deployment of an antifungal combination therapy to control the infection until the patient is stable enough for surgery or transplantation.
In conclusion, synergism and antagonism are in vitro concepts that are difficult to translate into clinical practice. Although there are experimental data on combination therapy, clinical studies, which could support the advantage of combination therapy over antifungal monotherapy in biofilm-associated infections, are needed but are hard to perform. Nevertheless, evidence of synergism of antifungal combination therapy in vitro might be the first step in establishing appropriate antifungal therapy.
